BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.
Share
Why It Matters
A stock expert still likes Akebia but thinks it's worth less money now. This tells you to watch if the company is running into money problems or slower sales.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.